RYTM Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 39.21%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.38%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 4.51%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Gilead Sciences, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.51% to investors and pays a quarterly dividend of $0.79 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 38.20x versus 5.41x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -19.69%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Moderna, Inc.'s return on equity of -30.18%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.38%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 42.09%. Given that Moderna, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Moderna, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is higher than Moderna, Inc.'s net income of -$200M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 38.20x versus 4.37x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of --. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.38%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $30.44 which suggests that it could grow by 10.75%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 38.20x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of --. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.38%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 163.74%. Given that Viking Therapeutics, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 38.20x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.